1. DNA Methylation in Autism Spectrum Disorders: Biomarker or Pharmacological Target?
- Author
-
Hanieh Gholamalizadeh, Maedeh Amiri-Shahri, Fatemeh Rasouli, Arina Ansari, Vafa Baradaran Rahimi, and Vahid Reza Askari
- Subjects
autism spectrum disorders ,DNA methylation ,epigenetics ,animal model ,biomarkers ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Autism spectrum disorder (ASD) is a group of heterogeneous neurodevelopmental disabilities with persistent impairments in cognition, communication, and social behavior. Although environmental factors play a role in ASD etiopathogenesis, a growing body of evidence indicates that ASD is highly inherited. In the last two decades, the dramatic rise in the prevalence of ASD has interested researchers to explore the etiologic role of epigenetic marking and incredibly abnormal DNA methylation. This review aimed to explain the current understanding of the association between changes in DNA methylation signatures and ASD in patients or animal models. We reviewed studies reporting alterations in DNA methylation at specific genes as well as epigenome-wide association studies (EWASs). Finally, we hypothesized that specific changes in DNA methylation patterns could be considered a potential biomarker for ASD diagnosis and prognosis and even a target for pharmacological intervention.
- Published
- 2024
- Full Text
- View/download PDF